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Limited proteolysisThe pleiotropic activities of Interleukin (IL-)6 are controlled by membrane-bound and soluble forms of the
IL-6 receptor (IL-6R) in processes called classic and trans-signaling, respectively. The coding single nucleo-
tide polymorphism (SNP) rs2228145 of the Interleukin 6 receptor (IL-6R Asp358Ala variant) is associated
with a 2-fold increase in soluble IL-6R (sIL-6R) serum levels resulting in reduced IL-6-induced C-reactive
protein (CRP) production and a reduced risk for coronary heart disease. It was suggested that the increased
sIL-6R level leads to decreased IL-6 classic or increased IL-6 trans-signaling. Irrespective of the functional
outcome of increased sIL-6R serum level, it is still under debate, whether the increased sIL-6R serum levels
emerged from differential splicing or ectodomain shedding. Here we show that increased proteolytic
ectodomain shedding mediated by the A Disintegrin and metalloproteinase domain (ADAM) proteases
ADAM10 and ADAM17 caused increased sIL-6R serum level in vitro as well as in healthy volunteers homo-
zygous for the IL-6R Asp358Ala allele. Differential splicing of the IL-6R appears to have only a minor effect on
sIL-6R level. Increased ectodomain shedding resulted in reduced cell-surface expression of the IL-6R Asp358Ala
variant compared to the common IL-6R variant. In conclusion, increased IL-6R ectodomain shedding is a mech-
anistic explanation for the increased serum IL-6R levels found in persons homozygous for the rs2228145 IL-6R
Asp358Ala variant.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Interleukin (IL-)6 plays an important role in health and disease [1,2].
The duration and strength of IL-6 cytokine-mediated signaling are
tightly regulated to avoid overshooting activities, e.g. acute-phase
response [3]. IL-6 activates signal transduction via homo-dimerization
of the ubiquitously expressed trans-membrane gp130 β-receptor,
which leads to subsequent activation of intracellular signaling pathways,
namely the Janus kinase/signal transducer and activator of transcription
(Jak/STAT), the phosphatidylinositide-3-kinase (PI3K) and the mitogen-
activated protein kinase (MAPK)-cascade pathway. To enable binding
to gp130, IL-6 needs an additional non-signaling IL-6 α-receptor
(IL-6R) [2,4], whose expression is restricted to hepatocytes and some
leukocyte populations. Consequently, IL-6 signaling is a priori limitedd Molecular Biology II, Medical
40225 Düsseldorf, Germany.
er).to membrane-bound IL-6R expressing cells, in a process referred to as
classic signaling [1,4].
However, a soluble form of the IL-6R (sIL-6R) is found in many body
ﬂuids. In concert with soluble gp130, also found in the serum, sIL-6R
might act as an IL-6 buffer system, limiting overshooting systemic IL-6 ac-
tions [5]. Paradoxically in trans-signaling, the sIL-6R in a complexwith IL-
6 is also able to induce signal transduction on cells which do not express
IL-6R but only gp130 [3]. In recent years, trans- but not classic signaling
was associated with chronic inﬂammatory diseases, such as rheumatoid
arthritis and inﬂammatory bowel disease [3]. The sIL-6R is generated by
two separate mechanisms: Limited proteolysis of the membrane-bound
IL-6R precursor (also called ectodomain shedding) and differential splic-
ing of the IL-6RmRNA. Ectodomain shedding of the IL-6R ismainlymedi-
ated by A Disintegrin and Metalloproteinase domain (ADAM) proteases
ADAM10 or ADAM17 [6,7]. Proteolytic cleavage of the IL-6R appears to
be the predominant mechanism, as it is believed to account for 90% of
the sIL-6R present in human serum.
The IL-6R single nucleotide polymorphism (SNP) variant rs2228145 is
associatedwith reduced C-reactive protein expression and a reduced risk
to develop coronary heart disease [8,9]. The IL-6R variant rs2228145
1486 C. Garbers et al. / Biochimica et Biophysica Acta 1842 (2014) 1485–1494leads to an amino acid substitution of aspartic acid to alanine (Ala)
at amino-acid position 358 within the extracellular domain of the IL-6R
(Asp358Ala) and is strongly associatedwith a two-fold increase in sIL-6R
levels [10,11]. In Europe, the Asp358Alamutation is rather common, as it
has aminor allele frequency (MAF) of 30–40% [12]. This SNPwas recently
shown to result in increased generation of the differentially spliced solu-
ble IL-6R [13], reduced cell surface expression of IL-6R [14] and impairedC p=0.004
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Fig. 1. The coding single nucleotide polymorphism (SNP) rs2228145 (Asp358Ala) is associated
IL-6R consisting of an Ig-like domain (D1), the two domains containing the cytokine-binding m
ADAM17 cleavage site between Gln357 and Asp358 is indicatedwith a black triangle. B. Chrom
wildtype situation (358Asp, A/A), whereas the lower panel shows a human homozygous for the
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levels within the serum was performed with an ELISA speciﬁc for hIL-6R. D. Serum levels of sg
sgp130. E. Serum levels of IL-6 were determined in the serum samples described under C wit
humans with the A/A or C/C IL-6R genotype (see Materials and methods for details). Equal am
the PBMCswas quantiﬁedwith an ELISA speciﬁc for the IL-6R. The data shown in this graph are
donors described under panel Cwere analyzedwith an ELISA that speciﬁcally recognizes only th
below the detection limit (b31.25 pg/ml) are shown with a symbol directly on the x-axis. In
individual participants. The horizontal lines indicate the mean of each group. P-values of the stIL-6 responsiveness of target cells indicating that the IL-6R Asp358Ala
variant is biologically active [15]. The amino acid exchange is directly
located within the ADAM17 cleavage site between Gln357 and Asp358
of the common IL-6R variant (Ala358) [16], whereas the cleavage site
for ADAM10was suggested to be located elsewhere [17]. It was hypothe-
sized that the IL-6RAsp358Ala variant has a higher proteolytic conversion
rate than the common IL-6R variant, concomitantly reducing IL-6p=0.5
250
0
200
150
100
50
A/A C/C
D
G
0
400
300
200
100
A/A C/C
p=0.016
C/C
B
Gln357/Asp358
A/A
Gln357/Ala358
C/C
.025
D
S-
sI
L-
6R
 [p
g/m
l]
sg
p1
30
 [n
g/m
l]
with increased soluble IL-6R levels in humans. A. Schematic representation of the human
odule (CBM, D2 and D3), the stalk region, transmembrane and intracellular domain. The
atograms showing the SNP rs2228145 (Asp358Ala) in exon 9 of IL6R. Upper panel shows a
mutation (358Ala, C/C). C. Full bloodwas taken from ﬁve healthy donors homozygous for
ontrols (referred to as A/A) by venipuncture and serum isolated. Determination of sIL-6R
p130 were determined in the serum samples described under C with an ELISA speciﬁc for
h an ELISA speciﬁc for human IL-6. F. PBMCs were isolated pair-wise from fresh blood of
ounts of PBMCs were incubated for 2 h, and the amount of sIL-6R in the supernatant of
themean± S.D. of ﬁve independent experiments. G. The serum samples of the 10 healthy
e differentially spliced hIL-6R, but not the sIL-6R generated by limited proteolysis. Samples
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atistical analysis are given above the respective ﬁgure.
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sion [15]. Importantly, all previously published point mutations and
deletions surrounding the ADAM17-cleavage site in the IL-6R lead to
decreased proteolytic conversion rates [16,17].
Here, we show that Asp358Ala confers higher constitutive and
induced proteolytic conversion rates of the IL-6R mainly mediated by
ADAM10 and ADAM17.
2. Materials and methods
2.1. Cells and reagents
Ba/F3-gp130 cells were obtained from Immunex (now part of
Amgen Inc., Thousand Oaks, CA, USA [18]) and Ba/F3-gp130-hIL-6R
cells described previously [19]. HEK293 and HeLa cells were obtained
from DMSZ (Braunschweig, Germany). Murine embryonic ﬁbroblasts
deﬁcient for ADAM10, ADAM17, or both have been described previously
[20–22]. Parental Ba/F3-gp130 cells were cultured using 10 ng/ml re-
combinant hyper-IL-6 [23,24], and after transduction with the different
IL-6R constructs with 10 ng/ml recombinant human IL-6 [25]. PMA and
ionomycin were purchased from Sigma-Aldrich (Steinheim, Germany).
The anti-hIL-6R mAb tocilizumab (RoACTEMRA) was kindly provided
by Roche (Grenzach, Germany) and GI254023X and GW280264X by
Glaxo Smith Kline (Stevenage, UK) [26].
2.2. Construction of the hIL-6R plasmids
pcDNA3.1 containing human IL-6R was previously described [7].
The point mutation hIL-6R-Asp358Ala was introduced using standard
techniques.
2.3. Retroviral transduction and proliferation assays of Ba/F3-gp130 cells
All necessary IL-6R constructs were subcloned into the pMOWS vec-
tor. Ba/F3-gp130 cells were retrovirally transduced [27] and cytokine-
dependent proliferation was determined as described previously [28].
2.4. Flow cytometry
IL-6R cell surface expression on transiently transfected HEK293
cells was stained with 1:100 diluted anti-hIL-6R 4–11 mAb [19] and a
1:100 dilution of FITC-conjugated anti-mousemAb (Dianova, Hamburg,
Germany) in FACS buffer (0.5% BSA in PBS). Cells were analyzed on a BD
FACS Canto II (Becton-Dickinson, Heidelberg, Germany) as described
previously [17].
2.5. IL-6R protein turnover assay
Ba/F3-gp130-hIL-6R and Ba/F3-gp130-hIL-6R-Asp358Ala cells
were collected and pelletized at 5000 rpm for 1 min. Supernatants
were discarded, and cells were suspended at a concentration of 1
× 106 cells/ml in ice cold PBS. Cells werewashed twice in ice coldwash-
ing buffer (0.5% BSA/PBS) and pelletized (300 g, 4 °C, 5 min). Cells were
afterwards incubated with anti-hIL-6R antibody on ice for 1 h. To
allow internalization, cells were washed 3 times with washing buffer
and incubated in DMEM with 10% FBS at 37 °C for the times indicated
(0–120 min). After the incubation, cells were washed three times
with washing buffer at 4 °C and subsequently incubated at 4 °C for 1
h with FITC-conjugated anti-mouse IgG. After additional washing, ex-
pression of receptors remaining at the cell surface was assayed as de-
scribed above.
2.6. Immunoﬂuorescence staining and confocal microscopy
HeLa cells were seeded onto glass coverslips in 6 well plates and
transiently transfected with either pcDNA3.1-hIL-6R or pcDNA3.1-hIL-6R_Asp358Ala using TurboFect (Thermo Scientiﬁc, St. Leon-Rot,
Germany). To determine transfection efﬁciency, cells were transfected
with a control plasmid containing GFP. GFP ﬂuorescencewas determined
microscopically and was detectable in 60–70% of the cells. 48 h after
transfection, cells were ﬁxed in 4% PFA for 20 min at room temperature.
After washing with PBS, cells were blocked for 1 h in PBS with 1% BSA
and 0.25% Triton X-100 for 1 h. Cells were stained with α-hIL-6R 4–11
mAb (diluted 1:500 in 1% BSA/PBS) at 4 °C over night. Afterwards, cells
were washed three times with PBS and stained with Alexa Fluor 546
goat anti-mouse IgG (Invitrogen, Karlsruhe, Germany, diluted 1:500 in
1% BSA/PBS) for 1 h at room temperature. Coverslips were washed
three times with PBS afterwards and mounted with ProLong Gold
Antifade reagent containing DAPI (Invitrogen, Karlsruhe, Germany)
onto microscopy slides. Analyses were performed with a Leica TCS SP2/
AOBSmicroscope equippedwith aHCXPLAPO63× immersion objective.
2.7. Genotyping and isolation of human peripheral bloodmononuclear cells
(PBMCs)
Ethic approval for this study was obtained from the institutional re-
view board of the Heinrich-Heine-University (study #3949). All partic-
ipants gave written informed consent. Genomic DNA was isolated from
buccal cells, part of the IL-6R ampliﬁed (5′: GAGGGGAAGGTTCCTTTG
AG, 3′: CATGGCATGCTTTTTGTAGC) and genotype determined by
sequencing. Afterwards, peripheral blood from healthy volunteers
was collected by venipuncture. PBMCs were isolated using LSM 1077
Lymphocyte Separation Medium (PAA Laboratories, Pasching, Austria)
analogous as described previously [19].
2.8. Shedding assays and ELISA
Shedding assays were performed as previously described [7], and
the data analysis and calculation was done according to Baran et al.
[17]. An ELISA speciﬁc for all hIL-6R variants [7,19] as well as an ELISA
speciﬁc for the differentially spliced shIL-6R (DS-sIL-6R)were described
previously [29]. The gp130 ELISA was from R&D Systems (Wiesbaden,
Germany), and the IL-6 ELISA was purchased from ImmunoTools
(Friesoythe, Germany).
2.9. Western blotting
Transiently transfectedHEK293 andMEF cells were lysed inmild lysis
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, complete
protease inhibitor mixture tablets), and 50 μg was loaded per lane onto
10% SDS gels. Western blotting using anti-human IL-6R [4–11] and anti
β-actin antibodies was performed as described previously [7,30].
2.10. Statistical analysis
Data are expressed as mean values ± standard deviation calculated
from at least three independent experiments unless otherwise stated.
Statistical analysis was performed using a one-tailed Mann–Whitney-
U test. P-values are either given directly within the ﬁgures, or a P-value
below 0.05 is indicated with an asterisk (*).
3. Results
3.1. Increased sIL-6R serum levels in homozygous carriers of the IL-6R SNP
rs2228145 (Asp358Ala variant) were not caused by differential splicing of
the IL-6R mRNA
The soluble IL-6R serum level is derived from differential splicing
or limited proteolysis of the membrane-bound IL-6R, and the latter is
believed to account for at least 90–99% of the total sIL-6R found in
human blood. ADAM10 and ADAM17 are themajor proteases responsi-
ble for IL-6R shedding, and the cleavage site of ADAM17 within the
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cated between Gln357 and Asp358 ([31] and Fig. 1A). Interestingly, the
single nucleotide polymorphism (SNP) rs2228145 resulted in an aminoA
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Fig. 3. Constitutive and stimulated shedding of the interleukin 6-receptor variant Asp358Ala is increased compared to the common IL-6R variant. A. HEK293 cells were transiently transfected
with expression plasmids coding for IL-6R wildtype and Asp358Ala. Cells were equally distributed one day later onto 6 well-plates, and stimulated 24 h later for 60min with 1 μM ionomycin
(Iono) or treatedwithDMSO as negative control. The soluble IL-6R in the supernatantwas quantiﬁed via ELISA. The amount of solublewildtype IL-6Rwas set to 100%, and all other valueswere
calculated accordingly. ELISA results show themean±S.D. of three independent experiments. B. The experimentwas performed as described under panel A, except that cells were stimulated
with 100 nM PMA for 120 min. C. HEK293 cells were transiently transfected with expression plasmids coding for IL-6R wildtype and Asp358Ala. Cells were equally distributed one day later
onto 6 well-plates. The next day, medium was replaced and conditioned media collected at the time points indicated. The soluble IL-6R in the supernatant was quantiﬁed via ELISA. C. The
experimentdescribed under panel Cwas performedwithNIH3T3 cells. E. The experimentwas performedas describedunder panel A. Cellswere pretreated for 30minwith themetalloprotease
inhibitors GI (speciﬁc for ADAM10) or GW (speciﬁc for ADAM10 and ADAM17) where indicated. One representative experiment of three performed is shown. F. The experiment was
performed as described under panel C, except that cells were stimulated with 100 nM PMA for 120 min. One representative experiment is shown.
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CD4+ regulatory T cells and monocytes, resulting in reduced IL-6 re-
sponsiveness of these cells [15]. Moreover, the IL-6R Asp358Ala variant
has been shown to be associated with increased sIL-6R level in the
serum of homozygous carriers [10,11]. To conﬁrm this ﬁnding, 37
healthy age-matched (25–35 years) volunteers were genotyped forFig. 2. The Asp358Ala IL-6R variant shows a reduced cell-surface expression and an increased pro
Asp358Ala or left untransfected. Cell surface expression of the IL-6Rwas determined viaﬂowcytom
of IL-6Rwithin the lysate determined via ELISA andWestern blotting. One representative experim
transfectedwith either IL-6Rwildtype or IL-6RAsp358Ala. Cellswere grownon cover slips,ﬁxed a
shown in red. Five different microscopic ﬁelds per IL-6R variant are shown. D. Equal amounts of B
hyper-IL-6, 10 ng/ml IL-6, 10 ng/ml IL-6 plus 100 μg/ml tocilizumab or left untreated. Cell viability
amounts of Ba/F3-gp130-hIL-6R and Ba/F3-gp130-hIL-6R-Asp358Ala cells were stained with anti
termined as described inMaterials andmethods. Cells were pretreated for 30minwith the ADAM
were stained with the anti-IL-6R antibody.the occurrence of the IL-6R SNP rs2228145 (15 A/A (wild-type, common
allele), 16 A/C (heterozygous), 6 C/C (rs2228145)), and sera were drawn
from ﬁve volunteers carrying the common IL-6R (A/A) allele and ﬁve
homozygous carriers of rs2228145 (C/C). Indeed, homozygosity for
the Asp358Ala mutation was associated with signiﬁcantly increased sIL-
6R serum levels (A/A: 26.4 ± 4.8 ng/ml; C/C: 44.0 ± 5.1 ng/ml; p =tein turnover. A. HEK293 cells were transiently transfected with either IL-6R wildtype, IL-6R
etry 48 h after transfection. B. The cells described under panel Awere lysed, and the amount
ent of three performed is shown. n. s.: No signiﬁcant difference. C. HeLa cellswere transiently
nd stained 48h later. TheDAPI stained nucleus is shown in blue,whereas the IL-6R staining is
a/F3-gp130-hIL-6R and Ba/F3-gp130-hIL-6R-Asp358Ala cells were stimulatedwith 10 ng/ml
was assessed 48h later. One representative experiment of three performed is shown. E. Equal
-IL-6R antibody, and the time-dependent protein turnover of the IL-6R (0–120min) was de-
10/17metalloprotease inhibitor GWwhere indicated. As control, parental Ba/F3-gp130 cells
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sIL-6R serum levels, since neither sgp130 (A/A: 170.9 ± 24.5 ng/ml;
C/C: 165.9 ± 21.9 ng/ml: p = 0.5; Fig. 1D) nor IL-6 (A/A: 17.8 ±
14.8 pg/ml; C/C: 19.2 ± 31.9 pg/ml; p = 0.21; Fig. 1E) showed any
statistical signiﬁcant difference between the two groups investigated.
Moreover, peripheral bloodmononuclear cells (PBMCs)were isolat-
ed from fresh blood samples of the ten volunteers, homozygous either
for the common or the IL-6R Asp358Ala allele. Blood was drawn on
ﬁve different days from age and sex-matched pairs (one genotype of
each on the same day), and cell culture supernatants were analyzed
for sIL-6R by ELISA. The data were analyzed pairwise on a daily basis,
to exclude qualitative differences between the preparations of the
cells on different days and subsequently summarized as x-fold increase
of sIL-6R using the sIL-6R levels from the daily prepared common IL-6R
variant as basis. As shown in Fig. 1F, conditioned cell culture superna-
tants of PBMCs homozygous for the Asp358Ala IL-6R variant contained
signiﬁcantly more sIL-6R (2.5 ± 1.1-fold, p = 0.025) compared to
homozygous carriers of the common IL-6R variant.Stephens et al. have previously shown that rs228145 increases
the differential splicing of the IL-6R [13]. Therefore, we analyzed if the
increased sIL-6R level were due to increased level of differentially
spliced sIL-6R (DS-sIL-6R). An ELISA speciﬁcally detecting the alterna-
tive C-terminus of DS-sIL-6R but not the proteolytically processed sIL-
6R revealed that below1%of the sIL-6R is generated bydifferential splic-
ing (Fig. 1G), which is consistent with other studies [32,33]. We can,
however, not exclude that the new C-terminus of the differentially
spliced sIL-6R variant is further processed after secretion, which might
lead to underestimation of the differentially spliced sIL-6R variants.
Four out of ﬁve serum samples from healthy volunteers, homozygous
for the C allele in rs2228145, had detectable DS-sIL-6R levels, whereas
in all other serum samples, DS-sIL-6R was below the detection limit
(b31.25 pg/ml) of the ELISA.
Even though our results conﬁrmed the earlier report that the
C/C genotype conferred increased production of spliced sIL-6R
as compared to the A/A variant [13], they suggested that ecto-
domain shedding but not differential splicing mechanism mainly
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Fig. 5. Primary human peripheral blood mononuclear cells (PBMCs) from individuals ho-
mozygous for the rs2228145 (Asp358Ala) variant show higher ectodomain shedding of
the IL-6R. PBMCs were isolated pair-wise from fresh blood of humans with the A/A or
C/C IL-6R genotype (see Materials and methods for details). In all experiments, equal
amounts of PBMCs were used, and the amount of sIL-6R in the supernatant of the
PBMCs quantiﬁed with an ELISA speciﬁc for the IL-6R. Cells were stimulated as follows:
A. 1 μM ionomycin (1 h), B. 100 nM PMA (2 h), C. 1 μM ionomycin plus either 3 μM GI
or GW, D. 100 nM PMA plus either 3 μM GI or GW. Cells were pre-incubated with the
inhibitors 30 min before addition of either PMA or ionomycin. P-values of the statistical
analysis are given above the respective ﬁgure.
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plasma.
3.2. The IL-6R Asp358Ala variant has an increased cell surface release rate
compared to the common IL-6R variant
Cell surface expression of the IL-6R Asp358Ala variant has been
shown to be reduced compared to the common IL-6R variant [14,15]
and human PBMCs release more sIL-6R (Fig. 1F), suggesting that
ectodomain shedding is the main driving force behind the increased
sIL-6R serum level. Interestingly, cell surface expression of the IL-6R
Asp358Ala variant in transiently transfected HEK293 cells was also
lower compared to the common IL-6R variant (Fig. 2A), even though
cellular IL-6R expression was comparable (Fig. 2B). Both IL-6R variants
were able to induce IL-6 dependent signaling in stable transduced
Ba/F3-gp130 cells, which could be blocked by themonoclonal antibody
tocilizumab (Fig. 2C). Using confocal microscopy, intense cell surface
staining for the common IL-6R variant was detected (Fig. 2D, top
panel), whereas the IL-6R Asp358Ala variant was only sparely detected
on the cell surface (Fig. 2D, lower panel). Taken together, ectopic
expression of the IL-6R Asp358Ala variant led to reduced cell-surface
expression compared to the common IL-6R variant, which resembles
the in vivo situation.
Next, we analyzed if an increased proteolytic turnover of the IL-6R
Asp358Ala variant contributes to the diminished amount of membrane-
bound IL-6R. Reduced overall cell surface expression of the Asp358Ala
IL-6R variant was also detected in Ba/F3-gp130-IL-6R cells (Fig. 2E). Cell
surface expressed IL-6R was labeled with hIL-6R antibodies on these
cells. Labeling was conducted at 4 °C and non-bound anti-IL-6R antibod-
ies were washed away. Cells were shifted back to 37 °C for 0, 30, 60, 90
and 120 min to allow IL-6R ectodomain shedding and internalization.
Thereafter, the cells were stained with secondary FITC-conjugated anti-
mouse IgG detection antibody at 4 °C to quantify the remaining cell
surface expressionof IL-6Rbyﬂowcytometry. During the pulse-chase ex-
periment, time-dependent reduction of the cell surface IL-6R expression
was faster for the IL-6R Asp358Ala variant compared to the common
IL-6R variant (Fig. 2E). To differentiate between ectodomain shedding
and receptor internalization, constitutive IL-6R shedding was blocked
by themetalloproteinase inhibitor GW280264X (GW), which is selective
for the main IL-6R sheddases ADAM10 and ADAM17. Inhibition of IL-6R
shedding had almost no effect on the cell surface expression of the
common IL-6R variant, suggesting that the reduction of IL-6R cell surface
expression was mainly caused by receptor internalization (Fig. 2E,
compare upper two panels). Interestingly, blockade of ADAM10 and
ADAM17 decelerated the cell surface down-regulation of the IL-6R
Asp358Ala variant almost to the rate observed for the common IL-6R var-
iant (Fig. 2E, compare lower two panels). Our data suggest that mainly
ectodomain shedding contributes to the accelerated IL-6R cell surface
down-regulation of the IL-6R Asp358Ala variant and directly cause the
increased sIL-6R levels.
3.3. The IL-6R Asp358Ala variant has an increased inducible proteolytic
conversion rate
Cellular stimulation with the calcium ionophor ionomycin or
the phorbolester PMA resulted in induced shedding of the IL-6R by
ADAM10 and ADAM17, respectively [7]. Therefore, we transiently
transfected HEK293 cells with cDNAs coding for either the common or
the Asp358Ala IL-6R variant and stimulated shedding with either
ionomycin or PMA.
We set the amount of sIL-6R after stimulation to 100% and calculated
all other values according to this, which allows the comparison of
the different IL-6R variants [17]. The amount of shed sIL-6R of the
Asp358Ala variant was slightly but signiﬁcantly increased compared to
the common IL-6R variant after ionomycin or PMA treatment (125 ±
2.4%, p b 0.05, Fig. 3A; 134.5 ± 13.7%, p b 0.05, Fig. 3B, respectively).Interestingly, also constitutively shed sIL-6R of the Asp358Ala IL-6R
variant was increased in HEK293 cells compared to the common IL-6R
variant (18.7 ± 5.2% vs. 27.7 ± 5.7%, p b 0.05, Fig. 3A; 17.2 ± 4.9% vs.
25.3± 4.9%, p b 0.05, Fig. 3B). Time-course experiments with transiently
transfected HEK293 (7 h) and NIH3T3 (4 h) conﬁrmed the increased
constitutive proteolytic sIL-6R release of the Asp358Ala variant (Fig. 3C
and D).
To ensure that ionomycin and PMA selectively activated ADAM10
and ADAM17, we used the protease inhibitors GI254023X (GI), which
is selective for ADAM10, and GW280264X (GW), which is selective for
both ADAM10 and ADAM17. Again, stimulation with ionomycin or
PMA induced more IL-6R shedding for the Asp358Ala variant, which
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These results conﬁrmed that ionomycin induced ADAM10-mediated
IL-6R shedding, whereas PMA selectively activated ADAM17 and that
both proteases contribute to increased shedding of the Asp358Ala
IL-6R variant.
3.4. ADAM10 and ADAM17 are responsible for increased proteolysis of the
Asp358Ala IL-6R variant
Next, we used murine embryonic ﬁbroblasts (MEFs) deﬁcient for
either ADAM10, ADAM17, or both proteases [7], to further analyze
shedding of the Asp358Ala IL-6R variant. Overall cellular expression
of the common and the Asp358Ala IL-6R variant was comparable or, ifA
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after PMA-treatment, since PMA solely activates ADAM17, which can-
not be compensated by ADAM10. Ionomycin-induced shedding led to
slightly more shed IL-6R in case of the Asp358Ala variant as compared
to the common variant (Fig. 4D). In MEFs deﬁcient for both ADAM10
and ADAM17 constitutive and PMA- and ionomycin-induced shedding
IL-6R shedding was completely abrogated for both IL-6R variants
(Fig. 4E). From these experiments we concluded that increased shed-
ding of the Asp358Ala IL-6R variant was mediated by ADAM10 and
ADAM17.
3.5. The Asp358Ala IL-6R variant has an increased inducible shedding
susceptibility on PBMCs
To conﬁrm our data in primary cells, we analyzed ectodomain shed-
ding of the IL-6R Asp358Ala variant on human PBMCs. Unstimulated
PBMCs from healthy volunteers had already shown a signiﬁcantly in-
creased sIL-6R release (2.5 ± 1.1-fold, p = 0.025) from PBMCs homo-
zygous for the Asp358Ala IL-6R variant (Fig. 1F). Thus, PBMCs were
used again from the ten volunteers, homozygous either for the common
or the IL-6R Asp358Ala allele. PBMCs were either stimulated with
ionomycin, PMA or left untreated to analyze induced IL-6R ectodomain
shedding. Stimulation with ionomycin or PMA strongly induced IL-6R
proteolysis of both IL-6R variants, shedding of the Asp358Ala IL-6R
variant was 1.8 ± 0.6 (p = 0.016) and 1.9 ± 0.3-fold (p = 0.075)
increased compared to common IL-6R variant, respectively (Fig. 5A, B).
Ionomycin and PMA-induced shedding was signiﬁcantly suppressed
by co-incubation with GI and GW or GW alone, respectively
(Fig. 5C, D), indicating that the sIL-6R was generated by ADAM10-
and ADAM17-mediated ectodomain shedding and not by differential
splicing.
3.6. Overexpression of protein kinase C strongly enhanced ADAM17-
mediated IL-6R shedding and abolished the differential shedding of the
IL-6R variants
PMA-induced ADAM17-mediated shedding of the IL-6R is dependent
on activation of the protein kinase C (PKCα) [35]. Co-transfection of
cDNAs coding for PKCα and the common IL-6R variant led to massively
increased constitutive and PMA-induced IL-6R shedding as compared
to IL-6R transfected HEK293 cells (p b 0.05, Fig. 6A), demonstrating
that the endogenous PKCα level is rate limiting for IL-6R shedding,
which was boosted by PKCα co-expression. Interestingly, co-expression
of IL-6R and PKCα abolished differences between the shedding of the
common and the Asp358Ala IL-6R variant (Fig. 6A). Inhibition of
ADAM17-mediated shedding by GW reduced PMA-induced shedding,
but not below the level of constitutive shedding (Fig. 6A), suggesting
that PKCαmight induce a so-far not-identiﬁed IL-6R sheddase. It is, how-
ever, not known if this unknown protease is also responsible for consti-
tutive shedding under non-PKCα-overexpressing conditions.
We veriﬁed these ﬁndings via ﬂow cytometry. Whereas we ob-
served only a very small reduction of cell-surface IL-6Rwhenwe stimu-
lated HEK293 cells transfected with wildtype IL-6R (Fig. 6B), the cell-
surface reduction of the Asp358Ala variant was more pronounced
after PMA stimulation (Fig. 6C), thus reﬂecting the ELISAmeasurements
(Fig. 6A). Interestingly, the majority of the IL-6R appeared to be still
present on the cell surface. This suggests that the endogenous level of
PKCα in HEK293 cells is not sufﬁcient to induce full-blown ADAM17-
mediated IL-6R shedding. In sharp contrast, PKC overexpression led to
an increased cell-surface loss of both IL-6R variants (Fig. 6D and E),
thereby conﬁrming the results obtained via ELISA measurement
(Fig. 6A). PKCα overexpression seemed not only to even the differences
between the common and the Asp358Ala variant of the IL-6R, but also
to lead to a preferential cleavage of the common variant (Fig. 6A,
D, E). The reason behind this is currently unknown andwarrants further
investigation.4. Discussion
Here, we provide evidence that the IL-6R SNP rs2228145 leads to
increased constitutive and induced ectodomain shedding of the IL-6R
by ADAM proteases. Overall steady state cell surface expression of
Asp358Ala IL-6R variant is reduced compared to the common IL-6R
variant. Paradoxically, despite reduced cell surface IL-6R expression,
inducing ectodomain shedding by ionomycin or PMA still resulted in
increased sIL-6R generation of the Asp358Ala IL-6R variant compared
to the common IL-6R variant. This effect might be explained by incom-
plete PMA- and ionomycin-induced shedding of the IL-6R, which is not
sufﬁcient to release all cell surface IL-6R molecules. This notion is sup-
ported by our PKC co-expression experiments. Forcing ectodomain
shedding of the IL-6R by over-expression of PKCα revealed the full po-
tential of IL-6R ectodomain shedding. Even though PMA is the strongest
inducer of IL-6R shedding described to date, co-expression of PKCα
resulted in 3–4-fold increase of PMA-induced IL-6R shedding revealing
the full potential of ADAM-mediated IL-6R shedding. Interestingly,
under these conditions no differences in PMA-induced shedding of the
common and the Asp358Ala IL-6R variants were observed.
Limited proteolysis of transmembrane proteins occurs usually in close
proximity to the plasma membrane, and the shedding susceptibility of
these substratesis critically inﬂuenced by the amino acids surrounding
the cleavage sites. ADAM17 cleaves the IL-6R between Gln357 and
Asp358 within the so-called stalk region [16], which consists of 52
amino acids [17]. The stalk region is considered to function as a spacer
to position the three extracellular domains of the IL-6R towards gp130.
Until now, no structural data of the stalk region are available [36,37],
but overall the stalk is considered to lack a domain structure. Interesting-
ly, other non-naturally occurring point mutations within the IL-6R
resulted in reduced shedding of the IL-6R [16]. Also small deletionswithin
the stalk region reduced IL-6R shedding [17]. To date, no consensus
sequence for ADAM10 or ADAM17 cleavage sites has been identiﬁed.
However, our data show that ADAM17 might favor the cleavage after a
small, non-charged amino acid like alanine instead of aspartic acid.
IL-6 is found in the blood at 1–5 pg/ml but increases to ng/ml con-
centrations during pathophysiology [1]. The serum concentration of
the sIL-6R is about 20 ng/ml and of sgp130 is about 100–200 ng/ml
[1]. The IL-6R SNP rs2228145 leads to a doubling of sIL-6R level in the
blood [10,11], and this has been shown to be associated with reduced
CRP level [8,9]. Two different mechanisms might be responsible for
this, ormay act in concert. Circulating IL-6will bind to sIL-6R and subse-
quently to sgp130, which is the natural inhibitor of the IL-6 trans-
signaling [1]. Thus, sIL-6R and sgp130 in the serum can act to buffer sys-
temic activities of IL-6. Since sgp130 is available in excess, a doubling of
sIL-6R would indeed increase this buffer capacity. However, thus far no
experiments were conducted to proof this hypothesis. An increased
proteolytic conversion of IL-6R due to the Asp358Ala SNP might there-
fore contribute to this increased buffer capacity of IL-6 and to overall re-
duced IL-6 activity [5,38]. Furthermore, the reduced membrane-bound
IL-6R on hepatocytes of humans homozygous for the rs2228145 SNP
might lead to reduced IL-6 classic-signaling and subsequently to
reduced CRP production [15,39].
Taken together, our data strongly suggested that ectodomain
shedding but not alternative splicing mainly contributes to the reduced
cell surface IL-6R levels and increased sIL-6R serum levels found in indi-
viduals homozygous for the IL-6R rs2228145 SNP.
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